ACTUATE THERAPEUTICS, INC. (ACTU) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-01

Key Insights

The reporting person, Paul J. Lytle, who is the Chief Financial Officer of Actuate Therapeutics, Inc., has been granted 105,000 employee stock options with an exercise price of $2.49 and a 10-year expiration date.
The options will vest over a 4-year period, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following 36 months.
This grant of stock options aligns the CFO's interests with those of the company and its shareholders, as it provides an incentive for the executive to work towards increasing the company's stock price over the long term.

Want the newest filings?

This analysis covers the filing from 2026-04-01. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-01

Andrew Paul Mazar, the Chief Operating Officer of Actuate Therapeutics, Inc. (ACTU), has been granted 105,000 stock options at an exercise price of $2.49 per share. The options will vest over a 4-year period, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following 36 months.
This stock option grant suggests that the company is incentivizing its key executive to drive the company's long-term growth and success.
Investors should monitor the trading patterns of insiders like Mazar to gauge their confidence in the company's prospects and potential catalysts.

Filed: 2026-04-01

The reporting person, Daniel M. Schmitt, acquired 237,000 stock options in Actuate Therapeutics, Inc. (ACTU) with an exercise price of $2.49 and a 10-year expiration date.
The options will vest over a 4-year period, with 25% vesting on the 1-year anniversary and the remaining 75% vesting in equal monthly installments over the following 3 years.
This insider acquisition of a significant equity stake indicates the CEO's confidence in the company's long-term prospects.

Filed: 2026-01-07

Insider Todd Thomson, a 10% owner and director, has sold 280,000 shares of Actuate Therapeutics (ACTU) at $5.80 per share.
Thomson's Kairos Venture Funds continue to hold significant indirect beneficial ownership in Actuate, totaling over 2.3 million shares.
The form indicates that Thomson and Kairos Venture Investments may be deemed to indirectly beneficially own the Actuate shares held by the Kairos Funds.

Other reports for ACTUATE THERAPEUTICS, INC.

Annual Report Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.